COVID-19 vaccine effectiveness
(Randomized evidence)

Search studies

Search by Vaccine name Author Registration number
Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, SSRN, 2021 (a)

Full text
Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

RCT
Phase 1
Healthy HIV-negative and seronegative adults at a single center in Vietnam N=60
Some concerns
Details

Full description

NCT04400838
AstraZeneca+University of Oxford
Voysey M, Lancet, 2020 ()
COV002

Full text
Commentary
Non replicating viral vector

ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (2·2 × 10¹? vp) /0.5mL (3.5 - 6.5 x 10¹?vp)

ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10¹?vp)

Meningococcal group A, C, W-135, and Y conjugate vaccine 0.5mL, 2 x doses, Days 0/28

RCT
Phase 2/3
Healthy adults in 18 centres in the UK N=10673
Some concerns
Details

Full description

ISRCTN89951424
AstraZeneca+University of Oxford
Voysey M, Lancet, 2020 ()
COV003

Full text
Commentary
Non replicating viral vector

ChAdOx1 nCoV-19 vaccine x 2 doses, Days 0/28, 0.5mL (3.5 - 6.5 x 10^10vp)

Meningococcal group A, C, W-135, and Y conjugate vaccine Day 0, saline 0.5mL (0.9% NaCl) Day 28

RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=10002
Some concerns
Details

Full description